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Fungal Infections Increase the Mortality Rate
Three-Fold in Necrotizing Soft-Tissue Infections
Christopher B. Horn, Brendan M. Wesp, Nicholas B. Fiore, Rohit K. Rasane, Marlon Torres,
Isaiah R. Turnbull, Obeid N. Ilahi, Laurie J. Punch, and Grant V. Bochicchio
Abstract
Background: Necrotizing soft-tissue infections (NSTIs) result in significant morbidity and mortality rates, with
as many as 76% of patients dying during their index admission. Published data suggest NSTIs rarely involve
fungal infections in immunocompetent patients. However, because of the recent recognition of fungal infections
in our population, we hypothesized that such infections frequently complicate NSTIs and are associated with
higher morbidity and mortality rates.
Methods: A prospectively maintained Acute and Critical Care Surgery (ACCS) database spanning 2008–2015
and including more than 7,000 patients was queried for patients with NSTIs. Microbiologic data, demographics,
and clinical outcomes were abstracted. Risk factors and outcomes associated with NSTI with positive intra-
operative fungal cultures were determined. Frequencies were compared by w2 and continuous variables by the
Student t-test using SPSS. Because the study included only archived data, no patient permission was needed.
Results: A total of 230 patients were found to have NSTIs; 197 had intra-operative cultures, and 21 (10.7%) of
these were positive for fungi. Fungal infection was more common in women, patients with higher body mass
index (BMI), and patients who had had prior abdominal procedures. There were no significant differences in
demographics, co-morbidities, or site of infection. The majority of patients (85.7%) had mixed bacterial and
fungal infections; in the remaining patients, fungi were the only species isolated. Most fungal cultures were
collected within 48 h of hospital admission, suggesting that the infections were not hospital acquired. Patients
with positive fungal cultures required two more surgical interventions and had a three-fold greater mortality rate
than patients without fungal infections.
Conclusions: This is the largest series to date describing the impact of fungal infection in NSTIs. Our data
demonstrate a three-fold increase in the mortality rate and the need for two additional operations. Consideration
should be given to starting patients on empiric anti-fungal therapy in certain circumstances.
Necrotizing soft-tissue infections (NSTIs) havebeen recognized as a clinical entity since at least the 5th
Century B.C.E., when they were described by Hippocrates
[1]. The first modern report was published in 1871 when it
was reported by a Confederate Army surgeon who described
2,642 cases of ‘‘hospital gangrene’’ [2]. Wilson later coined
the term ‘‘necrotizing fasciitis’’ to emphasize the character-
istic fascial involvement [3]. More recently, the term ‘‘nec-
rotizing soft-tissue infection’’ has been used to encompass
disease, not just of the fascia, but also of associated skin,
adipose tissue, and muscle [4, 5]. The infection remains rare,
with an estimated 3,800–5,400 cases in the United States
annually [6].
Historically, the mortality rate from NSTI has been as high
as 76%, but recent evidence suggests the overall mortality
rate has decreased to 4.9%–12% [6–10]. This large decrease
in deaths may be related to an emphasis on early recognition,
operative debridement, broad-spectrum antibiotics in pa-
tients with suspected NSTIs, and advances in critical care
[11–13].
Traditionally, NSTI has been categorized as Type I (poly-
microbial) or Type II (monomicrobial), with occasional refer-
ence to Type III (Vibrio vulnificus or other marine-dwelling
gram-negative organisms) [5,12,14, 15,16]. Cases of NSTI at-
tributed to fungal species have been reported, usually in im-
munocompromised or injured individuals [17–19].
Necrotizing soft-tissue infections attributed solely to fungi
have been described in case reports implicating species of As-
pergillus, Candida, and Cryptococcus [20–23]. Although the
majority of these cases occurred in immunocompromised
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individuals, a significant number of immunocompetent indi-
viduals also have been affected [24,25]. Moreover, cases of
NSTI attributable to fungi such asApophysomyces andRhizopus
have been documented in cases of natural disaster, as well as in
India, where its occurrence appears to bemore prevalent [19, 26,
27]. In these series, as many as 85% of patients were either at
higher risk for infection (immunosuppressed, history of diabe-
tes, etc.) or had suffered penetrating trauma [28–30].
Retrospective and prospective series of NSTI patients have
reported occurrences of fungal growth in Type I NSTIs at
rates from 2% to 10.9%, albeit with relatively small samples
[10,15,31,32]. There remains little analysis of the risk fac-
tors for and impact of fungal involvement in NSTI, and
neither the Surgical Infection Society (SIS) nor the Infectious
Disease Society of America (IDSA) recommends empiric
anti-fungal treatment [33, 34]. We hypothesized that fungal
species frequently complicate NSTI and are associated with
increased morbidity and mortality rates.
Patients and Methods
An Institutional Review Board-approved, prospectively
maintained, Acute and Critical Care Surgery (ACCS) da-
tabase spanning 2008–2015 and including more than 7,000
patients was queried for patients having a diagnosis of necro-
tizing fasciitis, gas gangrene, or Fournier’s gangrene (Interna-
tional Classification of Disease (ICD) 9 codes 728.86, 040.0,
and 608.83 respectively). All patients with ICD 9 diagnoses of
NSTI were evaluated by an investigator to confirm the accuracy
of coding information. Sites of infection, transfer data, micro-
biologic data, history of abdominal surgery, social history, im-
munosuppression, demographics, and clinical outcomes were
abstracted. The Charlson/Deyo Comorbidity Index (CCI) was
applied, and the Laboratory Risk Indicator for Necrotizing
Fasciitis (LRINEC) score was calculated as previously de-
scribed [35,36].
Microbiologic data were obtained solely from intra-operative
tissue or fluid cultures. Transfer was defined as transfer from any
hospital, rehabilitation facility, long-term acute-care hospital, or
skilled nursing facility. Abdominal surgery was defined as any
operation that violated the peritoneal cavity. Immunosuppres-
sion was defined as innate immunodeficiency, organ transplant
requiring immunosuppressive drug use, or chronic corticoste-
roid use. Human immunodeficiency virus (HIV) and malig-
nancy requiring chemotherapy were not included, as they are
Charlson co-morbidities [35].
At our institution, intra-operative tissue samples are trans-
ported in sterile containers and embedded directly in culture
medium. Fluid cultures are collected with flocked nylon swabs
and transported in Liquid Amies medium [37]. The swab and
medium are then vortexed and plated. All fungal samples are
plated on blood heart infusion and inhibitory mold agars. Non-
sterile specimens also are embedded or plated in Sabouraud
dextrose agar with chloramphenicol. Plates are incubated for
28 d at 30C and checked daily. Once grown, yeast species are
identified via matrix assisted laser desorption/ionization time-
of-flight mass spectrometry (MALDI-TOF MS). Molds are
identified with light microscopy (Melanie Yarbrough, PhD;
oral communication, February 25, 2017).
Risk factors for fungal infections were assessed by uni-
variable analysis. Frequencies were compared by Pearson’s
w2 and continuous variables by the Student t-test. Following
univariable analysis, multivariable logistic regression of
statistically significant predictors was used to determine in-
dependent factors predictive of fungal infection. Outcomes of
the patients with fungal infection were then compared with
those of patients without fungal infection. All data were an-
alyzed in SPSS version 23.
Results
A total of 230 patients were found to have NSTIs; 197 had
intra-operative cultures available and were included in the
analysis. Of these 197 patients, the average age was 50.4 y;
104 (57.8%) were male. The most common site of infection
was the groin and perineum (49.2%); the average age-adjusted
CCI was 3.2, and 21 (10.7%) of the NSTIs had positive intra-
operative fungal cultures. The demographics and univariable
analysis data are shown in Table 1.
Fungal infection was more common in women (71% vs.
44%; p= 0.019), in patients with a higher BMI (41.36 – 18.14
standard deviation [SD] vs. 34.36 – 12.69; p = 0.025), and in
patients with previous abdominal surgery (61.9% vs. 27.3%;
p = 0.001). There were no significant differences in other pa-
tient demographics, co-morbidities, sites of infection, transfer
status, or LRINEC score [36], although there was a trend to-
ward an abdominal site of infection. On multivariable analysis,
higher BMI (odds ratio [OR] 1.04 per kg/m2; 95% confidence
interval [CI] 1.0–1.1) and prior abdominal procedures (OR 4.6;
95% CI 1.60–13.4) were independent risk factors for fungal
infection (Table 2).
Of the positive fungal cultures, 12 (57.1%) grew Candida
albicans, one (4.8%) grew Candida dubliniensis, one (4.8%)
grew Apophysomyces trapeziformis, and eight (38.1%) grew
unspeciated yeasts. The majority of patients with positive
fungal cultures had a mixed fungal and bacterial infection
(18/21). Of the 18 patients with mixed infections, one had
Candida dubliniensis, eight had unspeciated yeast, and 10
had Candida albicans. The most common bacterial species
isolated were Escherichia coli and Bacillus fragilis. Com-
plete microbiology findings in the patients with mixed fungal
and bacterial NSTIs are shown in Table 3.
Of the three patients with solely fungal NSTIs, two had
Candida albicans and one hadApophysomyces trapeziformis.
All had been admitted to another healthcare facility prior to
transfer. The average time that fungal cultures were collected
was hospital d 3.5; however, a majority (11 patients or
52.4%) had cultures started within one d of admission. There
was no significant difference in the dates of collection be-
tween patients transferred and those who were admitted di-
rectly to our facility (3.0 – 3.9 vs. 5.2 – 7.5; p = 0.56).
Patients with fungal infections required more operations
(4.62 – 3.37 vs. 2.99 – 2.09; p = 0.042) and had a significantly
higher mortality rate (23.81% vs. 7.39%; p = 0.014). There
was no significant difference in hospital length of stay (LOS),
ventilator d, or intensive care unit LOS between cohorts.
However, in patients with fungal infections, there was a trend
toward longer ICU LOS, hospital LOS, and ventilator days
(Table 4).
Discussion
Previous literature has suggested that fungal infections are
rare in NSTI, although there are a number of case reports that
attest to their existence. These infections often are attributed















































Table 1. Demographics and Univariable Analysis of Patient Characteristics
Fungal Infection
Total Negative Positive P Value
n 197 176 21
Age 50.44 (15.15) 49.98 (15.7) 54.23 ( 8.85) 0.065
Gender (%) 0.019
Female 93 (47.2) 78 (44.3) 15 (71.4)
Male 104 (57.8) 98 (55.7) 6 (28.6)
Race (%) 0.523
Caucasian 122 (62.0) 112 (63.6) 10 (47.6)
African American 65 (33.0) 56 (31.8) 9 (42.9)
Hispanic 1 ( 0.5) 1 ( 0.6) 0
Native American 1 ( 0.5) 1 ( 0.6) 0
Other 1 ( 0.5) 1 ( 0.6) 0
Unknown 7 ( 0.6) 5 ( 2.8) 2 ( 9.5)
Body mass index (SD) 35.13 (13.51) 34.36 (12.69) 41.36 (18.14) 0.025
Social (%)
Alcohol 82 (41.6) 78 (44.3) 4 (19.0) 0.312
Illicit drug use 13 ( 6.6) 12 ( 6.8) 1 ( 4.8) 0.709
Tobacco 83 (42.1) 77 (43.8) 6 (28.6) 0.211
Co-morbidities (%)
Myocardial infarction 20 (10.2) 18 (10.2) 2 ( 9.5) 0.920
Congestive heart failure 28 (14.2) 26 (14.8) 2 ( 9.5) 0.515
Peripheral vascular disease 26 (13.2) 23 (13.1) 3 (14.3) 0.876
Cerebrovascular disease 6 ( 3.0) 6 ( 3.4%) 0 0.390
Dementia 1 ( 0.5) 1 ( 0.6) 0 0.729
Chronic pulmonary disease 39 (19.8) 36 (20.5) 3 (14.3) 0.502
Connective tissue disease 6 ( 3.0) 6 ( 3.4) 0 0.390
Peptic ulcer disease 5 ( 2.5) 5 ( 2.8) 0 0.434
Mild liver disease 12 ( 6.1) 10 ( 5.7) 2 ( 9.5) 0.487
Moderate or severe liver disease 3 ( 1.5) 2 ( 1.1) 1 ( 4.8) 0.200
Diabetes mellitus 67 (34.0) 58 (33) 9 (42.9) 0.365
Diabetes mellitus + organ damage 33 (16.8) 31 (17.6) 2 ( 9.5) 0.348
Hemiplegia 11 ( 5.6) 10 ( 5.7) 1 ( 4.8) 0.862
Renal disease 22 (11.2) 21 (11.9) 1 ( 4.8) 0.324
Any solid organ tumor 12 ( 6.1) 12 ( 6.8) 0 0.217
Metastatic solid organ tumor 10 ( 5.1) 9 ( 5.1) 1 ( 4.8) 0.945
Acquired immunodeficiency syndrome 1 ( 0.5) 1 ( 0.6) 0 0.729
Age-adjusted Charlson Comorbidity Index (SD) 3.2 ( 2.8) 3.2 ( 2.8) 3.0 ( 2.4) 0.721
Other immunosuppression (%) 28 (14.2) 26 (14.8) 2 ( 9.5) 0.515
History of abdominal surgery (%) 61 (31.0) 48 (27.3) 13 (61.9) 0.001
Transferred (%) 113 (57.4) 97 (55.1) 16 (76.2) 0.065
LRINEC Score 4.37 ( 2.26) 4.39 ( 2.27) 4.24 ( 2.17) 0.522
Site of infection (%)
Head/neck 4 ( 2.0) 4 ( 2.3) 0 0.485
Chest/upper back 11 ( 5.6) 9 ( 5.1) 2 ( 9.5) 0.405
Abdomen/lower back 58 (29.4) 48 (27.3) 10 (47.6) 0.053
Groin/perineum 97 (49.2) 86 (48.9) 11 (52.4) 0.761
Upper extremity 19 ( 9.6) 17 ( 9.7) 2 ( 9.5) 0.984
Lower extremity 86 (43.7) 78 (44.3) 8 (38.1) 0.587
The presence of fungal infection was diagnosed on the basis of intra-operative fluid or tissue culture.
Statistically significant differences are shown in boldface type.
SD = standard deviation.
Table 2. Multivariable Binomial Logistic Regression of Traits Associated
with Fungal Necrotizing Soft-Tissue Infection
Odds Ratio 95% Confidence Interval P Value
Prior abdominal surgery 4.628 1.600–13.389 0.005
Female sex 1.649 0.557– 4.881 0.366
Body mass index (kg/m2) 1.039 1.006– 1.074 0.020
















































to underlying trauma, immunosuppression, or foreign travel
[17–19]. Although the literature suggests a rate of fungal
infection between 2% and 10.9%, there has been no rigorous
analysis of risk factors or outcomes in fungal NSTI
[10,15,31,32]. In several studies, the culture source was not
specified [10,31]. Other studies specifically looked at intra-
operative cultures [15,32].We chose to look only at intra-
operative cultures in order to reduce the chances of including
fungemia caused by healthcare-acquired infections. Our
work demonstrated a rate of fungal infection of at least 10.7%
on intra-operative culture. At our institution, fungal cultures
are obtained from intra-operative samples only on surgeon
request, suggesting that the actual incidence of fungal in-
volvement may be higher than reported here. We further at-
tempted to assess whether fungi had been acquired in the
hospital by evaluating the day that fungal cultures were
collected. The majority (52.4%) of patients had cultures ta-
ken on hospital day 0 or 1, suggesting that the majority of
patients presented with the fungal infections. We further at-
tempted to determine if the infections were nosocomial by
assessing culture days as a function of transfer status. We
reasoned that if the infections were acquired in a healthcare
setting, patients transferring would have positive fungal
cultures sooner than those who had not been transferred.
However this was not the case. Taken together, we interpret
the data to suggest that most of these infections are present on
admission.
On univariable analysis, female gender, obesity, and prior
abdominal operations were associated with fungal infections.
Although abdominal and flank involvement did not reach
statistical significance, there was a trend toward more fungal
involvement in infections of these sites. On multivariable
analysis, increased BMI (OR 1.04 per kg/m2; 95% CI 1.0–
1.1) and prior abdominal procedures (OR 4.6; 95% CI 1.60–
13.4) were independent risk factors for fungal infection.
Surprisingly, immunosuppression was not associated with a
higher rate of fungal infection on either univariable or mul-
tivariable analysis. We specifically evaluated prior abdomi-
nal operations as a possible source of fungal infections
because of the predominance of enteric bacterial species in
the patients with fungal cultures and the trend toward ab-
dominal sites in patients with concomitant fungal infections,
suggesting a gastrointestinal source. This hypothesis is sup-
ported by data showing that yeasts colonize approximately
70% of healthy adult gastrointestinal tracts [38]. Although
there is a growing understanding of the mycobiome in various
disease states, there still is significant uncertainty as to the
role fungal species play in human disease [39].
Despite having similar co-morbidities and admission
LRINEC scores, patients with fungal infections had a higher
mortality rate than patients without. Although the LRINEC
score was designed as a diagnostic tool, previous retrospec-
tive studies have shown higher rates of death and limb loss
associated with higher scores, and as such, the score was used
as a marker for greater disease severity [36,40, 41]. Despite
no significant difference in LRINEC score, patients with
fungal infections required two additional operative debride-
ments. Patients with fungal infections also had a trend toward
longer hospital stays and ICU LOS, although the differences
did not reach statistical significance.
The overall mortality rate was 9.14%, similar to that in
most modern series. However, in patients with fungal infec-
tions, our data demonstrate a three-fold increase in the mor-
tality rate [6–10]. This is in contrast to work by Moore et al.,
which suggested that fungal infections are not predictive of
death; this may have been secondary to a small sample [32]. It
also is possible that local variation in the pathogenicity of
fungal species plays a role in this difference, as the paper by
Table 3. Bacteriology of Patients
with Fungal Involvement
Species No. (%)
Bacteroides fragilis 3 (14.3)
Enterococcus faecium 1 ( 4.8)
Pseudomonas aeruginosa 2 ( 9.5)
Staphylococcus aureus 2 ( 9.5)
Escherichia coli 3 (14.3)
Proteus mirabilis 1 ( 4.8)
Streptococcus agalactaiae 2 ( 9.5)
Coagulase-negative Staphylococcus 1 ( 4.8)
Acinetobacter calcoaceticus-baumannii complex 1 ( 4.8)
Klebsiella pneumoniae 1 ( 4.8)
Lactobacillus spp. 1 ( 4.8)
Klebsiella oxytoca 1 ( 4.8)
Eneterobactor cloacae 1 ( 4.8)
Prevotella 1 ( 4.8)
Mixed anaerobic micro-organisms 4 (19.0)
Mixed micro-organism 4 (19.0)
Mixed aerobic micro-organisms 4 (19.0)
Percentages sum to greater than 100% as several species occasion-
ally were present.
Table 4. Outcomes of Patients with Necrotizing Soft-Tissue Infection With and Without Fungal Infections
Fungal Infection
Overall Negative Positive P Value
n 197 176 21
Length of stay 14.6 (11.14) 13.81 ( 9.99) 21.29 (17.01) 0.061
ICU LOS 5.82 ( 7.45) 5.21 ( 6.22) 10.95 (13.25) 0.063
Ventilator d 1.69 ( 4.41) 1.45 ( 3.88) 3.62 ( 7.41) 0.202
No. of operations (SD) 3.17 ( 2.30) 2.99 ( 2.09) 4.62 ( 3.37) 0.042
Mortality rate (%) 18 ( 9.14) 13 ( 7.39) 5 (23.81) 0.014
The presence of fungal infection was diagnosed on the basis of intra-operative fluid or tissue culture.
Statistically significant differences are shown in boldface type.
ICU= intensive care unit; LOS= length of stay; SD = standard deviation.















































Moore et al. does not report fungal species [32]. It is unclear
why previous work has not shown a difference in outcomes in
patients with fungal infections. Similar-size studies have
shown comparable incidences of fungal involvement [15,32].
It is possible that this can be explained by local or temporal
variability in pathogenicity. Previous work has shown that
local variation in causative organisms and pathogenicity, even
within regions, is present and results in differences in pre-
sentation and outcomes [7], whereas other investigators have
shown temporal changes in causative organisms and patho-
genicity [42].
Our study has several limitations. Most notably, this was a
single-center review. The use of data from a single center and
the wide variability of presentation may limit wider appli-
cability, especially in light of the local variations in causative
organisms [7]. Further, although fungal infection was asso-
ciated with more deaths and operative debridements, it is
unclear whether the organisms are causative or simply in-
dicative of more severe infection. Anecdotal institutional
evidence suggests that treatment of fungal infection in pa-
tients with NSTI improves site healing; however, further
study is required.
In summary, this was a single-center study of 197 patients
with confirmed NSTI. Intra-operative cultures demonstrated
fungal infection in 10.7% of patients. This is the largest series
to date describing the impact of fungal involvement in NSTIs
in the United States. Fungal infection was associated with
a significantly higher mortality rate and a trend to a need for
additional operative procedures. Prior abdominal surgery
and higher BMI were independently associated with fungal
involvement. These results underscore the importance of
fungal cultures at index operation. Consideration should be
given to starting patients on empiric antifungal therapy on
presentation with NSTI until antibiotic therapy can be tai-
lored or discontinued.
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